Clinical trial · Interventional
Fertility Preservation in Female Cancer Patients
Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential
NCT01268592CI-TRIAL-00010108terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study technique has been declared part of standard care
Summary
Brief summary (as posted)
The purpose of this study is to preserve the fertility potential in females diagnosed with cancer by vitrifying (rapidly freezing) their oocytes (eggs) before undergoing treatment for their cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fertility | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| oocyte vitrification | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- positive cancer diagnosis
- description
- female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
- interventionNames
- Procedure: oocyte vitrification
Primary outcomes (1)
- measure
- successful pregnancy
- timeFrame
- nine months after transfer of embryo(s)
- description
- the primary objective of this study is the establishment of a successful pregnancy, following a disease-free interval after treatment for her cancer; this interval will be patient-dependent and will undoubtedly vary between participants.
Secondary outcomes (1)
- measure
- impact of stimulation on cancer recurrence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 14 Years
- Maximum age
- 42 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be 14-42 year old females with a cancer diagnosis. * Clearance letter from treating oncologist. * Approval by program oncologist or her designee. * Informed consent has to be signed after consultation with the program physician. Minors require consent of a parent or a legal guardian and assent from the participant. * Life expectancy (predicted by their malignancy) of 5 or more years. * Cancer diagnosis should have an expected cure rate of 50% or more, based upon clinico-pathologic features. Exclusion Criteria: * Patients whose oncologist and the program oncologist concur that immediate oncologic care should be rendered, not allowing sufficient time for a course of gonadotropin therapy and egg retrieval. * FSH level \>20 MIU/ml, indicating abnormal ovarian function. * Patients with stage IV cancers (\*age appropriate women with stage IV advanced Hodgkin's Lymphoma will be considered, as there is a significant long term survival rate with this advanced disease). * Patients with incurable cancer diagnoses. * Patients who are unable or unwilling to sign the informed consent. * Women cannot have an embryo transfer beyond age 50.
References
Publications (18)
- BACKGROUNDAjala T, Rafi J, Larsen-Disney P, Howell R. Fertility preservation for cancer patients: a review. Obstet Gynecol Int. 2010;2010:160386. doi: 10.1155/2010/160386. Epub 2010 Mar 31. PMID 20379357
- BACKGROUNDAzim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008 Jun 1;26(16):2630-5. doi: 10.1200/JCO.2007.14.8700. PMID 18509175
- BACKGROUNDAzim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007 Jun;92(6):2197-200. doi: 10.1210/jc.2007-0247. Epub 2007 Mar 13. PMID 17356042
- BACKGROUNDBlatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol. 1999 Jul;33(1):29-33. doi: 10.1002/(sici)1096-911x(199907)33:13.0.co;2-2. PMID 10401494
- BACKGROUNDEthics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005 Jun;83(6):1622-8. doi: 10.1016/j.fertnstert.2005.03.013. PMID 15950628
- BACKGROUNDGanz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005 Dec 19;118 Suppl 12B:136-41. doi: 10.1016/j.amjmed.2005.09.047. PMID 16414339
- BACKGROUNDGook DA, Edgar DH. Human oocyte cryopreservation. Hum Reprod Update. 2007 Nov-Dec;13(6):591-605. doi: 10.1093/humupd/dmm028. Epub 2007 Sep 10. PMID 17846105
- BACKGROUNDGrifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010 Feb;93(2):391-6. doi: 10.1016/j.fertnstert.2009.02.067. Epub 2009 May 12.